Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (55)

« Back to Publications

Immunogenicity of MVA-BN vaccine deployed as mpox prophylaxis: a prospective, single-centre, cohort study and analysis of transcriptomic predictors of response.

Drennan PG. et al, (2025), Lancet Microbe, 6

Early mucosal responses following a randomised controlled human inhaled infection with attenuated Mycobacterium bovis BCG.

Marshall JL. et al, (2025), Nat Commun, 16

Intravenous BCG vaccination in non-human primates induces superior serum antibody titers with enhanced avidity and opsonizing capacity compared to the intradermal route.

Peralta Alvarez MP. et al, (2024), Vaccine, 42

Evaluation of immune profiles associated with control of mycobacterial growth in systemic lupus erythematosus (SLE) patients.

Ongarj J. et al, (2024), Tuberculosis (Edinb), 148

Inhaled aerosol viral-vectored vaccines against tuberculosis.

Stylianou E. and Satti I., (2024), Curr Opin Virol, 66

Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial.

Wajja A. et al, (2024), Lancet Infect Dis, 24, 285 - 296

Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control.

Wajja A. et al, (2024), Lancet Infect Dis, 24, e78 - e79

Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants.

Satti I. et al, (2022), Nat Commun, 13

Functional in-vitro evaluation of the non-specific effects of BCG vaccination in a randomised controlled clinical study.

Wilkie M. et al, (2022), Sci Rep, 12

Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb-Infected Adults.

Riste M. et al, (2021), Vaccines (Basel), 9

A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates.

Tanner R. et al, (2021), NPJ Vaccines, 6

The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells.

Tanner R. et al, (2021), F1000Res, 10

Induction of Functional Specific Antibodies, IgG-Secreting Plasmablasts and Memory B Cells Following BCG Vaccination.

Bitencourt J. et al, (2021), Front Immunol, 12

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.

Wilkie M. et al, (2020), Vaccine, 38, 779 - 789

Cytomegalovirus infection is a risk factor for tuberculosis disease in infants.

Müller J. et al, (2019), JCI Insight, 4

Load More